Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 survodutide study in adults with MASH/NASH and F2-F3 liver fibrosis
NL-OMON61586Phase 3Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing survodutide with placebo (2 arms). Primary endpoints: Resolution of MASH without worsening of liver fibrosis, At least 1-point improvement in fibrosis stage with no worsening of MASH and 1 more. Started Apr 2025; status: recruiting.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NL-OMON61586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61586.